Michael T. Sweeney
Directeur Technique/Scientifique/R&D chez RESVERLOGIX CORP.
Fortune : 6 368 $ au 31/05/2024
Profil
Michael T.
Sweeney is currently the Senior Vice President-Clinical Development at Resverlogix Corp.
He previously worked as the Senior Director-Urology Global Medial Group Leader at Pfizer Inc. from 1995 to 2003.
From 2003 to 2007, he served as the Vice President-Medical Affairs at CV Therapeutics, Inc. He then worked as the Chief Medical Officer and VP-Research & Development at Assertio Therapeutics, Inc. from 2007 to 2014.
Additionally, he held the position of Senior Clinical Pharmacologist at Zeneca Group Plc.
Dr. Sweeney obtained a doctorate degree from The University of Liverpool.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
RESVERLOGIX CORP.
0,06% | 03/03/2023 | 155 312 ( 0,06% ) | 6 368 $ | 31/05/2024 |
Postes actifs de Michael T. Sweeney
| Sociétés | Poste | Début |
|---|---|---|
| RESVERLOGIX CORP. | Directeur Technique/Scientifique/R&D | 03/11/2014 |
Anciens postes connus de Michael T. Sweeney
| Sociétés | Poste | Fin |
|---|---|---|
Assertio Therapeutics, Inc.
 Assertio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL. | Directeur Technique/Scientifique/R&D | 01/01/2014 |
CV Therapeutics, Inc.
 CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Directeur Technique/Scientifique/R&D | 01/09/2007 |
| PFIZER, INC. | Corporate Officer/Principal | 01/01/2003 |
Zeneca Group Plc
 Zeneca Group Plc Pharmaceuticals: MajorHealth Technology Zeneca Group Plc used to develop & manufacture pharmaceutical products, agrochemicals and specialties chemicals. Its agrochemicals products include herbicides, insecticides and fungicides. The firm products were used by health care, agrochemical, paint, leather and imaging applications industries. The company was headquartered in London, UK. | Corporate Officer/Principal | - |
Formation de Michael T. Sweeney
| The University of Liverpool | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| RESVERLOGIX CORP. | Health Technology |
| PFIZER, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Health Technology |
Zeneca Group Plc
Zeneca Group Plc Pharmaceuticals: MajorHealth Technology Zeneca Group Plc used to develop & manufacture pharmaceutical products, agrochemicals and specialties chemicals. Its agrochemicals products include herbicides, insecticides and fungicides. The firm products were used by health care, agrochemical, paint, leather and imaging applications industries. The company was headquartered in London, UK. | Health Technology |
Assertio Therapeutics, Inc.
Assertio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL. | Health Technology |
